Dexcom Inc. | Large-cap | Healthcare
83,00 US$
1,23 %
| Dexcom Stock Comparison:
Dexcom vs Abbott LaboratoriesDexcom vs Boston ScientificDexcom vs StrykerDexcom vs Medtronic plcDexcom vs Edwards LifesciencesDexcom vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 4,0B
Gross Profit 2,4B 60,46 %
Operating Income 600,0M 14,88 %
Net Income 576,2M 14,29 %
EPS (Diluted) 1,42 US$

Balance Sheet Metrics

Total Assets 6,5B
Total Liabilities 4,4B
Shareholders Equity 2,1B
Debt to Equity 2,08

Cash Flow Metrics

Operating Cash Flow 1,1B
Free Cash Flow 630,7M

Revenue & Profitability Trend

Income Statement

Metric 2024 2023 2022 2021 2020
Revenue 4,0B 3,6B 2,9B 2,4B 1,9B
Cost of Goods Sold 1,6B 1,3B 1,0B 768,0M 646,6M
Gross Profit 2,4B 2,3B 1,9B 1,7B 1,3B
Operating Expenses 1,8B 1,7B 1,5B 1,4B 980,6M
Operating Income 600,0M 597,7M 391,2M 265,8M 299,5M
Pre-tax Income 709,0M 710,4M 390,8M 256,8M 225,0M
Income Tax 132,8M 168,9M 49,6M 39,9M -268,6M
Net Income 576,2M 541,5M 341,2M 216,9M 493,6M
EPS (Diluted) 1,42 US$ 1,30 US$ 0,82 US$ 0,39 US$ 1,27 US$

Income Statement Trend

Balance Sheet

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 4,3B 4,4B 3,7B 3,7B 3,4B
Non-Current Assets 2,2B 1,8B 1,7B 1,2B 865,7M
Total Assets 6,5B 6,3B 5,4B 4,9B 4,3B
Liabilities
Current Liabilities 2,9B 1,6B 1,8B 720,8M 614,1M
Non-Current Liabilities 1,4B 2,6B 1,4B 2,2B 1,8B
Total Liabilities 4,4B 4,2B 3,3B 2,9B 2,5B
Equity
Total Shareholders Equity 2,1B 2,1B 2,1B 2,0B 1,8B

Balance Sheet Composition

Cash Flow Statement

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 576,2M 541,5M 341,2M 216,9M 493,6M
Operating Cash Flow 1,1B 693,9M 792,8M 464,9M 446,0M
Investing Activities
Capital Expenditures -358,8M -236,6M -364,8M -389,2M -199,0M
Investing Cash Flow -207,5M -507,2M -521,5M -216,1M -1,0B
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -734,8M -318,6M -552,5M 10,4M 912,1M
Free Cash Flow 630,7M 511,9M 304,7M 53,3M 276,6M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 61,65
Forward P/E 40,39
Price to Book 14,18
Price to Sales 7,75
PEG Ratio 40,39

Profitability Ratios

Profit Margin 12,90 %
Operating Margin 12,91 %
Return on Equity 23,72 %
Return on Assets 5,98 %

Financial Health

Current Ratio 1,50
Debt to Equity 113,97
Beta 1,46

Per Share Data

EPS (TTM) 1,33 US$
Book Value per Share 5,78 US$
Revenue per Share 10,53 US$

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
dxcm 32,1B 61,65 14,18 23,72 % 12,90 % 113,97
Abbott Laboratories 232,9B 17,38 4,77 30,65 % 31,89 % 27,09
Boston Scientific 147,6B 72,80 6,64 9,50 % 11,58 % 52,16
Stryker 144,2B 50,99 6,89 14,26 % 12,31 % 82,92
Medtronic plc 111,9B 24,17 2,33 9,51 % 13,90 % 59,09
Edwards Lifesciences 44,1B 31,05 4,35 16,51 % 75,71 % 6,86

Financial data is updated regularly. All figures are in the company's reporting currency.